A new clinical trial update was registered on September 25, 2026, involving insulin degludec. The study, titled "Single-ascending Dose Study of HEC-151 Injection," is listed under identifier NCT07376200. This trial is designated as Phase 1 and its current status is recruiting. As a single-ascending dose study, the trial is designed to evaluate escalating doses of the investigational agent HEC-151 Injection. Insulin degludec appears in the trial context according to the available registry data. No results have been posted for this trial at this stage. The study status reflects that participant recruitment is ongoing rather than completed. No efficacy, safety outcomes, or comparative data are available from this listing. Details on trial design beyond phase and recruitment status were not provided in the event data. Insulin degludec remains an approved compound, and this trial update does not change its regulatory status. Readers interested in the specifics of the protocol can consult the official ClinicalTrials.gov registry entry. For additional background on insulin degludec, readers can consult the compound overview.
Phase 1 Trial of HEC-151 Injection vs Insulin Degludec Recruiting
See the full insulin degludec overview
Source: https://clinicaltrials.gov/study/NCT07376200